The incidence and prevalence data of Cholangiopathy related to AIDS is still insufficient. Although in prehighly active antiretroviral theraphy (HAART) era , the prevalence of the disease was reported as 26 percent to 46 percent only (Naseer M et al.,2018). Moreover, before the introduction of HAART, there is approximately only 250 cases reported in the literature. This problem is largely lacking especially from developing country. Although the cases is rarely reported, AIDS cholangiopathy remains an important differential diagnosis for chilestatic liver disease in which it is attributable to resistance for the first line antiretroviral medications especially in HIV-infected patients (Braitstein P. et al., 2006; as cited by Naseer M, 2018). The author further explains that among the reasons for the lacking of information in developing country including poor access to HAART resources, non-adherence with treatment plans and medications and lack awareness about the disease.